Keio University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Tokyo Japan (1858)

Organization Overview

First Clinical Trial
2001
NCT00125463
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Department of Internal Medicine, Keio University School of Medicine | Department of Internal Medicine School of Medicine Keio University | Division of Gastroenterology, Department of Internal Medicine, Keio University School of Medicine | Division of Rheumatology Department of Internal Medicine, Keio University | Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine | Emeritus Professor Keio University | Keio University | Keio University Hospital | Keio University School of Medicine | Keio University, School of Medicine | Nobuyuki Katori | School of Medicine, Keio University | Upper GI Research Center, Keio University School of Medicine

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 2)

Aortic Valve Stenosis (Phase 4)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Cardiovascular Diseases (Phase 4)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Crohn Disease (Phase 3)

Dwarfism, Pituitary (Phase 3)

Endocrine System Diseases (Phase 3)

Growth Disorders (Phase 3)

Hyperlipidemias (Phase 4)

Hypertension (Phase 4)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Peptic Ulcer (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Stomach Neoplasms (Phase 2)

Ulcer (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial APIs: 45